Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies.
Authors: Berglund A K, Schnabel L V
Journal: Equine veterinary journal
Summary
# Editorial Summary: MHC-Mismatched Equine MSCs and Immune Recognition Allogeneic mesenchymal stem cells hold considerable promise for treating equine musculoskeletal injuries, yet uncertainty persists regarding whether recipient horses mount an effective immune response against MHC-mismatched donor cells. Berglund and Schnabel investigated this fundamental question by exposing equine bone marrow-derived MSCs to serum from horses previously sensitised to allogeneic cells, then measuring cytotoxic antibody binding and cell death through complement-dependent and antibody-dependent cellular cytotoxicity pathways. Their findings demonstrated that MHC-mismatched MSCs were indeed recognised and targeted for destruction by cytotoxic anti-MHC antibodies, suggesting that allogeneic stem cell therapies may face significant immunological barriers in previously exposed or immunologically primed recipients. These results have direct clinical implications: practitioners utilising off-the-shelf allogeneic MSC products should be aware that repeat treatments or use in sensitised horses may result in rapid cell death, potentially explaining variable therapeutic outcomes and supporting the case for MHC-matched or autologous cell sources in horses with prior exposure to allogeneic tissues.
Read the full abstract on PubMed
Practical Takeaways
- •Allogeneic MSC treatments using MHC-mismatched cells may have reduced efficacy due to immune-mediated rejection; consider autologous or MHC-matched sources when available
- •Cytotoxic antibody responses to mismatched cells could limit the therapeutic window and require immunosuppressive protocols to extend cell survival
- •When using allogeneic MSCs clinically, screening for MHC compatibility or preparing for potential immune rejection is important for treatment planning
Key Findings
- •Allogeneic MHC-mismatched equine bone marrow-derived MSCs are recognized by the recipient immune system
- •Cytotoxic antibodies are generated against MHC-mismatched MSCs, targeting them for death
- •MHC compatibility is a critical consideration for allogeneic MSC transplantation in horses